
Sales of the Genmab-developed bone marrow cancer drug, Darzalex, which Johnson & Johnson has licensed, surpassed projections for the first quarter of 2022, as revealed by Johnson & Johnson’s financial report on Tuesday.
Darzalex sales came to USD 1.86bn compared to the consensus analyst estimate of USD 1.67bn, according to Bloomberg News.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app